PM
PCRX icon

Prosight Management’s Pacira BioSciences PCRX Stock Holding History

Prosight Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-94,362
Closed -$2.76M – 54
2024
Q1 		$2.76M Sell
94,362
-164,062
-63% -$5.04M 0.77% 33
2023
Q4 		$8.72M Sell
258,424
-951,953
-79% -$27.9M 3.5% 11
2023
Q3 		$37.1M Buy
1,210,377
+332,791
+38% +$12M 11.77% 1
2023
Q2 		$35.2M Buy
877,586
+786,463
+863% +$32.5M 10.29% 1
2023
Q1 		$3.72M Buy
+91,123
New +$3.63M 1.76% 24
2020
Q3 		– Sell
-55,000
Closed -$2.89M – 56
2020
Q2 		$2.89M Buy
+55,000
New +$2.3M 1.24% 26

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's PCRX Position: Q2 2024 in Review

Prosight Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 94,362 shares — an estimated $2.76M sold.

Prosight Management first reported a position in PCRX in Q2 2020 and held it in 6 quarters. The position peaked at $37.1M in Q3 2023. 282 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Prosight Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Prosight Management sold 94,362 Pacira BioSciences shares in Q2 2024, an estimated $2.76M.
  • Prosight Management first reported a position in Pacira BioSciences in Q2 2020 and held it in 6 quarters.
  • Prosight Management's Pacira BioSciences position peaked at $37.1M in Q3 2023.
  • 282 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.